JNJ

Johnson & Johnson

Oct 10 • 04:00PM ET

190.72

-0.36 -0.19 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM DGRO IWD

Index	DJIA, S&P 500	P/E	20.40	EPS (ttm)	9.35	Insider Own	0.12%	Shs Outstand	2.41B	Perf Week	1.10%
Market Cap	459.32B	Forward P/E	16.72	EPS next Y	11.40	Insider Trans	-7.02%	Shs Float	2.41B	Perf Month	6.85%
Enterprise Value	491.20B	PEG	2.89	EPS next Q	2.76	Inst Own	73.91%	Short Float	0.76%	Perf Quarter	21.62%
Income	22.66B	P/S	5.07	EPS this Y	8.75%	Inst Trans	0.34%	Short Ratio	2.09	Perf Half Y	28.27%
Sales	90.62B	P/B	5.85	EPS next Y	5.07%	ROA	12.10%	Short Interest	18.18M	Perf YTD	31.88%
Book/sh	32.60	P/C	24.33	EPS next 5Y	7.06%	ROE	30.21%	52W High	192.10 -0.72%	Perf Year	19.43%
Cash/sh	7.84	P/FCF	24.76	EPS past 3/5Y	-9.49% 0.55%	ROIC	19.25%	52W Low	140.68 35.57%	Perf 3Y	15.51%
Dividend Est.	5.19 (2.72%)	EV/EBITDA	16.81	Sales past 3/5Y	-1.79% 1.58%	Gross Margin	68.12%	Volatility	1.65% 1.49%	Perf 5Y	28.66%
Dividend TTM	5.08 (2.66%)	EV/Sales	5.42	EPS Y/Y TTM	34.88%	Oper. Margin	24.02%	ATR (14)	2.78	Perf 10Y	103.04%
Dividend Ex-Date	Aug 26, 2025	Quick Ratio	0.76	Sales Y/Y TTM	4.69%	Profit Margin	25.01%	RSI (14)	75.89	Recom	2.08
Dividend Gr. 3/5Y	5.43% 5.54%	Current Ratio	1.01	EPS Q/Q	18.30%	SMA20	4.72%	Beta	0.36	Target Price	189.60
Payout	84.80%	Debt/Eq	0.65	Sales Q/Q	5.76%	SMA50	6.96%	Rel Volume	1.09	Prev Close	191.08
Employees	139800	LT Debt/Eq	0.50	Earnings	Oct 14 BMO	SMA200	18.23%	Avg Volume	8.69M	Price	190.72
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.29% 3.89%	Trades		Volume	9,598,019	Change	-0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$212
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$206
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform

Show Previous Ratings

Today 06:46AM	J&J in talks to acquire Protagonist Therapeutics (Pharmaceutical Technology)
06:10AM	Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? (Motley Fool)
Oct-12-25 07:46AM	Stocks dip as government shutdown continues, rare earths rally: What to watch this week (Yahoo Finance)
06:00AM	What to Expect in Markets This Week: Big Bank Earnings, Fed Speakers, Shutdown Data Delays (Investopedia)
Oct-10-25 09:08PM	3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR (Zacks)
04:20PM	Loading…
04:20PM	Johnson & Johnson recommends shareholders reject "mini-tender" offer by Tutanota (Business Wire)
02:35PM	Stock Market Today: Dow Plunges On Trump China Threat; J&J Sends This Stock Soaring (Live Coverage) (Investor's Business Daily)
02:21PM	Trump's China tariff threat sinks stocks, Applied Digital surges (Yahoo Finance Video)
12:19PM	Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. (Barrons.com)
12:10PM	Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know (Zacks)
11:53AM	Protagonist Therapeutics stock surges after J&J acquisition talks report (Investing.com)
11:23AM	Protagonist Stock Surges on Johnson & Johnson Report (The Wall Street Journal)
11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
11:06AM	Big Banks Gear Up to Report Q3 Earnings (Zacks)
10:32AM	Pre-markets Up Slightly to Start Friday Trading (Zacks)
07:30AM	Loading…
07:30AM	Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress (PR Newswire)
04:19AM	Is This Beaten-Down Dividend King a Buy? (Motley Fool)
Oct-09-25 04:24PM	Johnson & Johnson to Participate in the UBS Global Healthcare Conference (Business Wire)
03:26PM	A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here's Who It Is. (Barrons.com)
01:29PM	Stock Market Today: Dow Falls But These Blue Chips Buck Drop; These Techs Eye New Entries (Live Coverage) (Investor's Business Daily)
12:45PM	The Week Ahead: Inflation Data, Bank Earnings on Deck (Schaeffer's Research)
10:57AM	BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers (Zacks)
09:52AM	BDTX Stock Hits 52 Week High: Is There More Room for Growth? (Zacks)
09:15AM	Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings (Zacks)
09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Oct-08-25 02:48PM	Finally, Tariffs the Stock Market Likes. Why Pharma Levies May Do the Trick. (Barrons.com)
12:10PM	Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again (Zacks)
11:23AM	Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease (Zacks)
10:49AM	Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
08:42AM	Loading…
08:42AM	3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal (Zacks)
08:14AM	Earnings Season Is Starting. Can Strong Profits Keep the Stock Market Rally Going? (Barrons.com)
07:16AM	Why AbbVie and Johnson & Johnson Could Outperform Pfizer (MarketBeat)
05:48AM	Medtech M&A has remained slow this year. But 2 execs are ready to make a deal (MedTech Dive)
01:43AM	Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks (Insider Monkey)
Oct-07-25 08:58PM	Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio (Motley Fool)
09:34AM	The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance (Zacks)
08:05AM	TREMFYA (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis (PR Newswire)
08:05AM	Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill (PR Newswire)
08:00AM	Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses (PR Newswire)
Oct-06-25 05:07PM	Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson (Zacks)
04:00PM	Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference (Business Wire)
02:21PM	Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants (MarketBeat)
01:43PM	Earnings Are Coming. Wall Street Hopes Strong Profits Can Keep the Market Rally Going. (Barrons.com)
08:32AM	How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results (Zacks)
08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
Oct-04-25 05:01PM	Jim Cramer Believes Lawsuits Are No Longer a Major Threat to Johnson & Johnson (Insider Monkey)
Oct-03-25 05:45PM	Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts (Zacks)
05:10PM	Stocks to Watch Recap: Apple, Applied Materials, Chevron, Broadcom (The Wall Street Journal)
04:21PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)
03:17PM	Johnson & Johnson Stock Climbs As Wells Fargo Boosts Rating And Price Target (GuruFocus.com)
02:07PM	Dow touches above 47,000, while J&J stock receives upgrade (Yahoo Finance Video)
01:04PM	Stocks to Watch Friday: Apple, Applied Materials, Chevron, Broadcom (The Wall Street Journal)
10:16AM	Wells Fargo sees room to run for Johnson & Johnson, highlights pharma upside (Investing.com)
09:42AM	Apple downgraded, Alibaba upgraded: Wall Street's top analyst calls (The Fly)
06:27AM	Barclays Maintains a Hold Rating on Johnson & Johnson (JNJ) With a $176 PT (Insider Monkey)
Oct-02-25 02:31PM	Elon Musk Becomes First Person Worth $500 Billion, Tesla CEO's Wealth Is Now Larger Than Palantir, Alibaba (Benzinga)
07:06AM	Boston Scientific aims for market leadership in electrophysiology (MedTech Dive)
03:08AM	Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer (Insider Monkey)
02:55AM	Johnson & Johnson (JNJ) Gains FDA Nod for TREMFYA Subcutaneous Therapy (Insider Monkey)
Oct-01-25 07:38PM	Analyst Report: Johnson & Johnson (Morningstar Research)
07:04PM	Chart Master: A breakout could signal more upside for beaten-down pharma stocks (CNBC TV)
04:55PM	Drug Stock Rally Helps Push Dow and S&P 500 to Records (The Wall Street Journal)
11:11AM	Marla Beck Steps Down as CEO of Hydrafacial Owner (WWD)
11:10AM	Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End (Barrons.com)
10:13AM	ISRG Expands SP Indications: A Game Changer in Colorectal Surgery? (Zacks)
05:31AM	Bristol Myers, Takeda to pool data for AI-based drug discovery (Reuters)
04:44AM	Should You Buy Kenvue Stock After Its 30% Plunge? (Motley Fool)
Sep-30-25 05:14PM	Pfizer Stock Surges After Company Makes a Deal With President Trump (The Wall Street Journal)
04:38PM	Stocks Post Late Rally After Trump Strikes Deal With Pfizer (The Wall Street Journal)
02:04PM	Jim Cramer on Johnson & Johnson: "It's Differentiating Itself From the Pack" (Insider Monkey)
07:35AM	J&J gets FDA approval for Tremfya in paediatric psoriasis (Pharmaceutical Technology)
06:30AM	Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus (The Daily Upside)
04:00AM	Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets (Insider Monkey)
Sep-29-25 04:25PM	Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus (Investor's Business Daily)
03:15PM	The AI Rally Is on Pause. Try These 11 Non-Tech Stocks. (Barrons.com)
01:37PM	Johnson & Johnson (JNJ): A Dividend Aristocrat With Unmatched Stability (Insider Monkey)
08:00AM	U.S. FDA approves TREMFYA (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor (PR Newswire)
Sep-28-25 06:15PM	Why Johnson & Johnson Could Be the Ultimate Dividend King (Motley Fool)
Sep-27-25 10:44AM	Johnson & Johnson (JNJ) to Withdraw the LINC Reflux Management System from Markets Outside the U.S. (Insider Monkey)
Sep-26-25 10:48PM	'I'm an optimist,' says Johnson & Johnson CEO on its R&D investment (CNBC TV)
08:48PM	Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato (CNBC TV)
05:45PM	Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
11:45AM	Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE? (Zacks)
09:58AM	Trump's new tariffs on pharma, furniture, & trucks: What to know (Yahoo Finance Video)
09:14AM	Big pharma stocks rise as Street reacts to latest presidential tariff plan (Associated Press Finance)
08:11AM	What to Expect From Johnson & Johnsons Q3 2025 Earnings Report (Barchart)
07:21AM	Could This Single Dividend King Make Your Portfolio Worth $1 Million in 20 Years? (Motley Fool)
05:06AM	J&J: Still a Defensive Giant, or Too Dependent on Pharma? (GuruFocus.com)
04:41AM	Is pharmas IRA pricing battle running out of steam? (Pharma Voice)
03:17AM	Trump Plans New Tariff Push With 100% Rate on Patented Drugs (Bloomberg)
Sep-25-25 04:15PM	Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board (Business Wire)
12:53PM	Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment? (Zacks)
11:52AM	AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold? (Zacks)
11:45AM	Johnson & Johnson (JNJ) Could Be a Great Choice (Zacks)
09:55AM	Josh Brown Talks About Johnson & Johnson's (JNJ) Upcoming 'Big Catalyst' (Insider Monkey)
09:00AM	Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know (Zacks)
04:52AM	These 3 Dow Stocks Are Set to Soar in 2025 and Beyond (Motley Fool)
03:15AM	3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years (Motley Fool)
Sep-24-25 07:30PM	Why This Dividend King Still Stands Tall (Barchart)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Option Exercise	101.87	56,471	5,752,701	234,484	Sep 05 06:00 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Sale	177.81	56,471	10,040,883	178,013	Sep 05 06:00 PM
Taubert Jennifer L	Officer	Sep 04 '25	Proposed Sale	177.81	56,471	10,040,904		Sep 04 02:37 PM
Forminard Elizabeth	Executive VP, General Counsel	Aug 29 '25	Option Exercise	115.67	11,521	1,332,634	22,423	Sep 03 05:13 PM
Forminard Elizabeth	Officer	Aug 29 '25	Proposed Sale	177.20	9,570	1,695,806		Aug 29 03:36 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Option Exercise	101.87	125,824	12,817,691	401,791	Aug 25 07:12 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Sale	179.21	125,824	22,548,655	275,967	Aug 25 07:12 PM
Duato Joaquin	Officer	Aug 22 '25	Proposed Sale	180.03	125,824	22,652,724		Aug 22 01:58 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Option Exercise	101.87	16,820	1,713,453	30,820	Aug 18 06:19 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Sale	176.91	16,820	2,975,571	14,000	Aug 18 06:19 PM
Wolk Joseph J	Officer	Aug 15 '25	Proposed Sale	176.91	16,820	2,975,571		Aug 15 03:57 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Jul 17 '25	Sale	163.55	19,137	3,129,830	10,658	Jul 18 04:12 PM
REED JOHN C	Officer	Jul 17 '25	Proposed Sale	163.55	19,137	3,129,831		Jul 17 04:05 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience